As discussed earlier in the broader context of cancer therapy, the clinical outcome of pharmacologic targeting of macrophage IKKβ/NF-κB activities may depend on the disease stage; that is, premalignant, malignant or metastatic. This evidence concerns the gene IKBKB and cancer.